CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing
This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing.
Overview
Frank Leonard, Chief Executive Officer of NovoCure Limited (NASDAQ:NVCR), reported an open-market sale of 34,273 common shares for a transaction value of ~$615,000 on June 4, 2026, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 reported price ($17.93); post-transaction value based on June 4, 2026, market close ($17.99).
Details
* 1-year performance is calculated using June 4th, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.